Vascular Surgeon Dr. Jeffrey Lawson to Address VEITHSymposium

Clinical Work and Data will be presented on Humacyte’s Novel Bioengineered Blood Vessel

RESEARCH TRIANGLE PARK, N.C.--()--Jeffrey H. Lawson, M.D., Ph.D, Vice Chair for Research, Professor of Surgery and Pathology at Duke University Medical Center (Durham, North Carolina), Director of the Vascular Research Laboratory and Director of Clinical Trials for the Department of Surgery, will be presenting at the leading vascular specialist conference, VEITHSymposium, on November 22nd in New York City.

Dr. Lawson will present ‘Clinical Experience with Tissue Engineered Grafts in Hemodialysis Access’ on Saturday, November 22nd at 1:56 p.m.

Laura Niklason, M.D., Ph.D., who is the founder of the regenerative medicine company Humacyte, and Dr. Lawson have collaborated for over a fifteen years and laid the groundwork for the bioengineered off-the-shelf blood vessel that is under development. Dr. Lawson currently serves as a consultant to the North Carolina-based Humacyte.

“A tremendous medical need exists for vascular access grafts in patients with end-stage renal disease, and advances in tissue engineering have led to an investigational off-the-shelf bioengineered blood vessel for implantation. This novel vessel has the potential to be a real advance for these patients who need a new vascular tissue for sustainable dialysis access,” said Dr. Lawson. “I look forward to sharing these developments, and the possibility that this technology not only has the potential to be used in dialysis access but for vascular replacement throughout the body. Preclinical data has shown the potential to offer an alternative to the current standard of care.”

The bioengineered blood vessel is made by cultivating donated human cells on a tubular scaffold. The vessel is then decellularized, or cleansed, of the qualities that are likely to trigger an immune response. In July, the Food and Drug Administration granted ‘Fast Track’ designation for the potential approval of this tissue engineered vessel for vascular access in hemodialysis patients, expediting the regulatory review process. In pre-clinical tests, this bioengineered vessel has performed better than other synthetic and animal-based implants.

Humacyte is currently engaged in multi-center, early phase clinical trial testing in both the United States and Poland. Dr. Lawson has collaborated on preclinical and clinical studies, and is a principal investigator for Humacyte’s study in patients with end stage renal disease (ESRD).

In addition to his talk on Humacyte’s data, Dr. Lawson will also being speaking on ’Management of Hypercoagulable States in Patients with End Stage Renal Disease’ on Saturday, November 22nd.

ABOUT HUMACYTE

Humacyte, Inc., a privately held company founded in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. The company web site is www.humacyte.com.

Contacts

ICR
Matthew Lindberg, 203-682-8214
matthew.lindberg@icrinc.com

Release Summary

Vascular Surgeon Dr. Jeffrey Lawson to Address VEITHSymposium

Contacts

ICR
Matthew Lindberg, 203-682-8214
matthew.lindberg@icrinc.com